Lost for over 100 years, World War 1 era US submarine found along with bomber that sank in same area in 1950
USS F-1 Tragedy
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
In a historic deep-sea expedition off the coast of San Diego, researchers have captured stunning, never-before-seen imagery of the U.S. Navy submarine USS F-1 , which sank on December 17, 1917, following a fatal collision during a training exercise. The accident claimed the lives of 19 crew members, whose final resting place has now been thoroughly surveyed and documented using state-of-the-art underwater technology.The high-resolution images of the World War I-era submarine were taken during a joint research expedition conducted from February 24 to March 4, 2025, by the Woods Hole Oceanographic Institution (WHOI) and several interagency partners, including the U.S. Navy, the National Science Foundation (NSF), and the Naval History and Heritage Command (NHHC).Using advanced deep-sea imaging tools such as the human-occupied vehicle (HOV) Alvin and the autonomous underwater vehicle (AUV) Sentry, researchers successfully located the submarine more than 1,300 feet (400 meters) below the surface.The mission also captured detailed imagery of a U.S. Navy Grumman TBF Avenger torpedo bomber that crashed nearby during a training flight in 1950.'Advanced ocean technology and simple teamwork played a big part in delivering these new images,' said Bruce Strickrott, senior pilot of Alvin and manager of WHOI's Alvin Group. 'As a U.S. Navy veteran, it was a profound honor to visit the wreck of the F-1 with our ONR and NHHC colleagues aboard Alvin.'The discoveries were made during a scheduled training and engineering dive intended to test equipment and develop new deep-sea research techniques. Alongside the technology trials, the expedition served as a somber reminder of the risks faced by sailors past and present.'It was an incredibly exciting and humbling experience to visit these historically significant wrecks and to honor the sacrifice of these brave American Sailors,' said Brad Krueger, underwater archaeologist for the NHHC, who completed his first dive aboard Alvin to visit the F-1 site.The USS F-1, originally conducting a 48-hour performance test, was lost when it collided with the USS F-3 in dense fog. Only three crew members survived. More than a century later, the wreck has been found lying intact on its starboard side, remarkably preserved by the deep-sea environment.To honor the fallen, a remembrance ceremony was held aboard the research vessel Atlantis, where the names of the 19 lost sailors were read aloud, and a bell rang 19 times—once for each life lost.'The Navy has a solemn responsibility to ensure the legacies of its lost Sailors are remembered,' said Krueger. 'History and archaeology are all about people, and we felt it was important to read their names aloud.'Advanced imaging tools, including multi-beam sonar and high-resolution cameras, enabled the creation of 3D photogrammetric models of the submarine and bomber wrecks. These reconstructions provide not only educational and historical value but also serve as crucial training assets for future oceanographic missions.'We were careful and methodical in surveying these historical sites so that we could share these stunning images, while also maintaining the reverence these sites deserve,' said Anna Michel, NDSF chief scientist and co-lead of the expedition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
9 hours ago
- New Indian Express
HIV prevention: Gilead's vaccine breakthrough nears EU approval
CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still rapidly spreading HIV epidemic, in the world with the European Medicines Agency's (EMA) advisory committee issuing a positive opinion for its twice-yearly injectable, lenacapavir. EMA the decision on Thursday (July 24) clears the way for approval by the European Commission later this year, following similar regulatory clearance in the United States in June 2025. Lenacapavir, a HIV pre-exposure prophylaxis (PrEP), is to be marketed in Europe under the brand name Yeytuo, is a long-acting injectable designed to prevent HIV infection with just two subcutaneous doses annually, following an initial oral lead-in. This innovative therapy is part of a new class of HIV-1 capsid inhibitors that disrupt multiple stages of the viral replication cycle. It represents the first and only twice-yearly PrEP option for individuals at risk of HIV, offering a significant alternative to the currently available daily oral pills like Truvada (TDF/FTC). Clinical trials have demonstrated strong efficacy. In the PURPOSE 1 trial, conducted among over 5,000 cisgender women and adolescent girls in South Africa and Uganda, lenacapavir achieved 100% efficacy—zero new HIV infections were reported in the treatment group. A second trial, PURPOSE 2, involving a broader group of cisgender men, transgender, and non-binary adults, showed a 96% reduction in HIV risk compared to those on daily PrEP. These results prompted early unblinding of both trials due to overwhelming benefit. Participants also reported high satisfaction with the twice-yearly regimen, citing ease of adherence, reduced stigma, and fewer missed doses compared to daily pills. Gilead's chief medical officer, Dr. Dietmar Berger, was on Friday quoted in reports saying that lenacapavir 'has the potential to become a critical tool for public health,' especially for individuals who face barriers to consistent healthcare access. The product is expected to play a vital role in addressing rising HIV infections in Europe, where more than 24,700 new diagnoses were reported in 2023—an 11.8% increase from the previous year across the EU, Iceland, Liechtenstein, and Norway. Beyond Europe, Gilead is pursuing a global access strategy for lenacapavir. The company has licensed the drug for generic production in 120 low-and lower-middle-income countries and is working toward WHO prequalification and inclusion in international HIV prevention guidelines. It is also eligible for EU-M4all procedures, which would streamline regulatory pathways for resource-limited settings.
Time of India
15 hours ago
- Time of India
'Safety remains a top priority': Nasa says 20% of workforce to depart space agency; here's why
AP file photo Around 20% of Nasa's workforce is expected to leave the agency, a spokesperson of the agency confirmed to news agency Reuters on Friday. Roughly 3,870 employees are projected to depart, although the figure could change in the coming days and weeks After the departures, Nasa's workforce would stand at 14,000 employees. The shake-up comes as the Trump administration moves to cut staff and faces growing concerns over steep budget reductions for the agency. "Safety remains a top priority for our agency as we balance the need to become a more streamlined and more efficient organization and work to ensure we remain fully capable of pursuing a Golden Era of exploration and innovation, including to the Moon and Mars," stated Nasa spokesperson Cheryl Warner as quoted by CBS News. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo The White House has proposed cutting Nasa's science budget by nearly 50 per cent. 'We are losing some of the brightest minds of our time,' said Democratic leader George Whitesides, a former Nasa chief of staff and the vice-ranking member of the House committee overseeing the agency. 'It will have terrible implications for decades to come,' he was quoted as saying to Politico. Nasa employs around 17,000 people, but about 80 per cent of those expected to leave are senior officials. These are top-level leaders responsible for major engineering projects, such as Mars rover missions. The staff drain would result in depriving the agency of 'highly specialized, irreplaceable knowledge crucial to carrying out Nasa's mission,' said Nasa administrator Sean Duffy. Other major centres like the Johnson Space Center, Nasa headquarters, Langley Research Center, Kennedy Space Center, and Marshall Space Flight Center are set to lose around 400 employees each, according to Politico. These centers handle most of Nasa's human spaceflight operations, aviation research, rocket launches, and engineering work. Without them, the agency is incapable of running the International Space Station, send payloads into orbit, or plan missions to the Moon. The Goddard Space Flight Center under Nasa is set to witness the exiting of nearly 800 of its 3,000 staff. The center is responsible for space probes and major projects, such as infrared space telescopes.
The Hindu
a day ago
- The Hindu
Science retracts NASA arsenic bacteria paper after years of controversy
In 2010, in the waters of Mono Lake in California, NASA-funded scientists claimed to have found a microbe called GFAJ-1 they said rewrote biology. It had allegedly replaced the phosphorus in its DNA with the toxic element arsenic. The announcement, made at a high-profile press conference on December 2 that year, stunned the world. The findings, soon published in the journal Science, hinted that life could rely on a radically different chemistry. Lead author and microbial geobiologist Felisa Wolfe-Simon declared, 'Life as we know it may be due for a revision.' Speculation surged: had NASA stumbled onto alien biology? Set the ball rolling On July 24 this year, Science announced that it would be retracting the GFAJ-1 paper, nearly 15 years after its splashy debut, citing shifting editorial standards and lingering public confusion. 'It's important to have any groundbreaking work independently evaluated before drawing far-reaching conclusions,' University of Minnesota synthetic biologist Kate Adamala said. 'We want the public to be excited, but the message must match the strength of the data.' Mainstream media amplified the drama. One headline read: 'NASA Discovers Life Not As We Know It'. Ivan Oransky, co-founder of Retraction Watch, a site that tracks withdrawn papers and promotes research transparency, and executive director of The Centre for Scientific Integrity, saw the media blitz as pivotal. 'Without the hype, this paper might never have been retracted.' He pointed to NASA's style of communication as a key factor in the storm that followed in 2010. 'Historically, NASA hasn't always had a respectful relationship with journalists,' he said. 'They're great at promoting themselves, and sometimes at overselling.' Peer review in public To the people at large, the prospect of arsenic life hinted at alien biochemistry. But for many scientists, the GFAJ-1 paper raised more questions than answers. Critics began pointing out that arsenate is unstable in water, so its role in DNA seemed chemically implausible. 'If true, this would have overturned nearly a century of data, but nothing in the chemistry suggested it was possible,' Steven Benner, an early critic and chemistry professor at University of Florida said. Others were initially intrigued. 'I was very excited and impressed. It was a big deal in the origins community,' Adamala, then a graduate student, said. But like many, her enthusiasm waned as flaws emerged. Microbiologist Rosemary Redfield became a leading critic and one of the first replicators to disprove the findings. 'It's a fine example of how easy it is for scientists to be misled by an attractive hypothesis and of why we need both formal peer review and informal outside scrutiny.' By late December, the backlash gained traction. Blogs and Twitter (now turned the paper into a case study on post-publication peer review. Sheila Jasanoff, professor of science and technology studies at Harvard, noted that while such public spaces can foster valuable crowd-sourced peer review, they also risk overreach. 'These days science, like true crime, has spilled outside the constraints of officially authorised review. However, like all forms of democratisation, such informal policing can run out of control if it is driven by a mob mentality that is out to shame or undermine a researcher or a research program.' The original team stood by their findings — but by now the tone had shifted. Evidence falls apart Over the next 18 months, multiple labs tested the paper's core assertion. In 2012, Science published two studies that refuted it. Redfield's team found no arsenate in GFAJ-1's DNA. Tobias Erb's group confirmed the microbe still needed phosphorus to grow, i.e. it hadn't rewritten biology, just tolerated low-phosphate conditions. Wolfe-Simon maintained that her team's methods showed arsenic was incorporated into DNA and were robust enough to rebut Benner's contamination claims. Science didn't retract or flag the paper, saying claims should be resolved by further research, not editorial action. And since no fraud was alleged, the rebuttals sufficed. 'The whole debate ends up circling around the semantics of words like 'error', 'fraud', 'misconduct,'' Oransky said. 'But this paper, let's be honest, has been understood as unreliable since at least 2012, if not earlier.' Why science took so long For Benner, the GFAJ-1 paper reflected differences in scientific perspectives. Biologists saw phosphorus as essential, chemists knew arsenate's instability, geologists accepted mineral substitutions, and astrobiologists embraced radical possibilities. 'It wasn't that reviewers were incompetent,' Benner said. 'They just didn't all speak the same scientific language.' He saw another deeper flaw. NASA's astrobiology community often relies on consensus panels that falter when no one challenges ideas outside their domain. 'Multidisciplinary science is essential,' he said, 'but when it's superficial, weak claims slip through. This wasn't peer review breaking down: it was different communities assuming they shared standards while working from very different assumptions.' Adamala echoed this concern: 'Young scientists in interdisciplinary fields should embrace continuous peer review, as reliance on collaborators' expertise can miss flaws that later scrutiny might catch.' Correction sans closure 'They're right to retract a paper whose high-profile conclusions were entirely wrong,' Redfield said. One senior researcher noted that the Committee on Publication Ethics (COPE) guidelines, which many journals have adopted as a measure to improve research integrity, justify a retraction if the findings are unreliable. Here, multiple labs found phosphate in the arsenate medium, undermining the paper's core claim that the microbe grew by substituting arsenic for phosphorus. 'The growth experiments at the heart of the paper were flawed,' the researchers said. 'Even if it was an honest mistake, the core conclusions didn't hold up.' Adamala said that it's a good example of self-regulation in science. 'Slowly but surely, mistakes do get corrected.' Oransky was more measured: 'Science is now acting on an expanded definition of retraction that's consistent with what's been possible for a long time, but rarely used.' Not everyone sees it as black and white. Jasanoff warned that retractions can erase the very messiness that makes science work. 'Rather than draw hard lines between truth and error, science advances through open debate,' she said. 'It's better to preserve a record that shows how scientists test, challenge, and refine their ideas, even when plausible claims later prove wrong.' Benner, for his part, expressed worry that broadening retraction policies could weaken the informal scrutiny that exposed the paper's flaws, raising questions about balancing error correction with preserving the scientific process. Today, the whole saga has transformed into a cautionary tale. Adamala said the controversy may have cast a shadow over exotic chemistry research in astrobiology, making scientists more cautious about bold claims. Who pays the price? Wolfe-Simon's rise and fall was swift. In 2010, she was hailed for a potential revolution in biology. Two years later, she quietly exited both NASA and mainstream science, her research career derailed by controversy and lack of funding. 'Good scientists would have responded by getting back into the lab and doing the necessary follow-up work. But these authors still don't admit mistakes,' Redfield said, pointing to their rebuttal letter in response to the retraction. Ariel Anbar, a coauthor of the now retracted paper, said, 'Science cited no misconduct or specific mistake. We stand firmly by the integrity of our data.' He also criticised the journal for not sharing a blog post it published regarding the retraction with the authors, calling it a breach of COPE guidelines. Oransky disagreed: 'What guideline is this referring to? Furthermore, standing by your data doesn't mean there aren't errors in it.' Anbar also said the team rejected 'the alleged error' and that it was raised in 2011 and rebutted in a peer-reviewed exchange. 'They may reject it,' Oransky replied, 'but that seems to be the rationale for the retraction.' Nonetheless, Oransky also said Science's retraction notice could have been clearer. He explained that retractions often imply misconduct, so when Science called the paper unreliable but not unethical, it still put the authors on the defensive. 'You can see that here, they're saying: 'But there was no misconduct. No clear error.'' Jasanoff said she doesn't see it completely as an individual failure. She argued that the unusually long delay until retraction may reflect less a concern with scientific uncertainty and more with a broader institutional tendency to manage reputation, especially in an era of heightened fears over misinformation. Wolfe-Simon's arc underscored a stark truth: high-risk discoveries bring both acclaim and vulnerability. When science goes public, its failures play out just as visibly as its triumphs, leaving lasting questions about how to correct course without crushing the people behind the work. A slow machine Peer-reviewers cleared GFAJ-1 and media hype propelled it, but shifting editorial norms more than new data undid it 15 years later. Oransky singled out Science's editor-in-chief, Holden Thorp, for leading that shift. 'Other journals have done it, but he's been consistently engaged in a way that encourages open conversation, no matter whether people agree with specific decisions or not.' That kind of editorial openness, he added, may be the real legacy of the arsenic life saga. Jasanoff, however, cautioned that every retraction risks erasing the visible, iterative debate that builds trust. 'It is better for people to understand that science moves through trial and error, and gradual self-correction. It is not a binary. All science is provisional.' Benner drew a parallel to the 1976 Viking missions, where a premature 'no organics, no life' verdict in Science stifled debate. 'Calling the ballgame early had an unfortunate result. It prevented the dialectic the scientific process needs.' The arsenic life case endures not because of its flawed claim, but for what it revealed about the pressures shaping modern science: how spectacular findings — especially from institutions like NASA — can short-circuit scrutiny, and how correcting course means confronting the very systems that made such claims irresistible in the first place. Anirban Mukhopadhyay is a geneticist by training and science communicator from Delhi.
